(esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

Most common AE is myelosuppression, GI side effect, and transient hypertension. There were no treatment-related deaths. Results are consistent with the data reported on the first 19 patients in Study ...

A comprehensive analysis of the Phase II EBV CTL trial conducted at NCCS that identifies biomarkers will be presented at the ...

Incorporating perioperative durvalumab into treatment with neoadjuvant chemotherapy and radical cystectomy prolongs ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

由安徽医科大学第一附属医院、蚌埠医学院第一附属医院、安徽省公共卫生临床中心、泰莱生物合著的学术成果《血浆游离 5-羟甲基胞嘧啶：高潜力的胃肠癌症无创检测生物标志物》被 ESMO ASIA 收录，刊载于 Annals of Oncology 中 ...

NIAGARA received a warm reception when it was presented at the ESMO cancer congress, with discussant Petros Grivas from the University of Washington and Fred Hutchinson Cancer Center in Seattle ...

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...